SCHEMBL4007672

SCHEMBL4007672

Cc1cc2[nH]nc(-c3ccccc3)c2cc1N

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 2/20 0.57
DCLK1 O15075 1/20 0.57
PRKD3 O94806 1/20 0.57
MAP4K4 O95819 1/20 0.57
CHEK2 O96017 1/20 0.57
CSF1R P07333 1/20 0.57
FER P16591 1/20 0.57
MARK3 P27448 1/20 0.57
FLT4 P35916 1/20 0.57
FLT3 P36888 1/20 0.57
MAPK9 P45984 1/20 0.57
CSNK1D P48730 1/20 0.57
CLK2 P49760 1/20 0.57
CSNK2A1 P68400 1/20 0.57
CSNK1G2 P78368 1/20 0.57
MAP4K2 Q12851 1/20 0.57
STK3 Q13188 1/20 0.57
CAMK2B Q13554 1/20 0.57
CAMK2G Q13555 1/20 0.57
DYRK1A Q13627 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22446034 0.82 MAP2K4 (0.59) CDK2DCLK1PRKD3MAP4K4CHEK2
SCHEMBL16862707 0.80 MAPK10 (0.67) CDK2DCLK1PRKD3MAP4K4CHEK2
SCHEMBL11682988 0.77 ALDH1A1 (0.62) CDK2DCLK1PRKD3MAP4K4CHEK2
SCHEMBL31677101 0.77 ALDH1A1 (0.62) CDK2DCLK1PRKD3MAP4K4CHEK2
SCHEMBL4008208 0.76 DCLK1 (0.65) CDK2DCLK1PRKD3MAP4K4CHEK2
SCHEMBL31423230 0.76 DCLK1 (0.65) CDK2DCLK1PRKD3MAP4K4CHEK2
SCHEMBL4005413 0.76 MAP2K4 (0.65) CDK2DCLK1PRKD3MAP4K4CHEK2
SCHEMBL4093740 0.76 MAP2K4 (0.71) CDK2DCLK1PRKD3MAP4K4CHEK2
SCHEMBL5552470 0.76 AXL (0.69) CDK2DCLK1PRKD3MAP4K4CHEK2
SCHEMBL20810555 0.75 LRRK2 (0.51) CDK2DCLK1PRKD3MAP4K4CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473701-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2009-01-06 US disclosed
CN-100369899-C Substituted indazoles with anti-cancer activity AVENTIS PHARMA SA (FR) 2008-02-20 CN disclosed
CN-1642922-A Substituted indazoles with anti-cancer activity AVENTIS PHARMA SA (FR) 2005-07-20 CN disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 US disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 CDK2 10/4885DCLK1 525/4885PRKD3 88/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 CDK2 28/4885DCLK1 563/4885PRKD3 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.